Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trial

Abstract Low-dose interleukin 2 (Ld-IL2) has shown therapeutic effects in autoimmune diseases, particularly systemic lupus erythematosus (SLE), yet optimal dosage has not been established in clinical trials. In this multicentre, double-blind, phase IIb trial, 152 patients with active SLE were random...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Xia Zhang, Ruiling Feng, Yifan Wang, Wenqiang Fan, Xiao Gao, Miaomiao Ma, Guanmin Gao, Dongbin Jiang, Ting Li, Huifang Guo, Lingyan Lei, Ke Xu, Yucui Li, Kuanting Wang, Yan Ding, Wei Wei, Na Zhang, Wenping Pan, Qingwen Wang, Juan He, Yueming Cai, Tongjun Mao, Ruijun Zhang, Rong Mu, Yongfu Wang, Hui Wang, Yuan Jia, Xiaolin Sun, Zhanguo Li, Jing He
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Portfolio 2026-04-01
Saila:	Nature Communications
Sarrera elektronikoa:	https://doi.org/10.1038/s41467-026-72245-7
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!